AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming
Biochemical and Biophysical Research Communications · 2023-11 · 680 · 7-14
DOI: 10.1016/j.bbrc.2023.09.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023-11. Verfasst von Kyungtaek Im und 9 weiteren Autor:innen. Beteiligte Einrichtung: Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea, Ministry of Health and Welfare.
Abstract (Originalsprache)
AXL is a member of TAM receptor family and has been highlighted as a potential target for cancer treatment. Accumulating evidence has uncovered the critical role of the AXL signaling pathway in tumor growth, metastasis, and resistance against anti-cancer drugs, as well as its association with cancer immune escape. However, the function of AXL as a manipulator of the immune system in the tumor microenvironment (TME) remains unclear. Therefore, in this study, we investigated the impact of AXL on immune cells in the TME of a syngeneic tumor model using AXL knockout (AXL-/-) mice. Compared to AXL wild-type (AXL+/+) mice, tumor growth was significantly suppressed in AXL-/- mice, and an induced population of tumor-infiltrated CD8+ T cells and CD103+ dendritic cells (DCs) was observed. The change of CD8+ T cells and CD103+ DCs was also confirmed in tumor-draining lymph nodes (TdLN). In addition, the clonal expansion of OVA-specific CD8+ T cells was dominant in AXL-/- mice. Finally, anti-PD-1 treatment evidenced synergistic anti-cancer effects in AXL-/- mice. Overall, our data indicate that AXL signaling may inhibit the clonal expansion of tumor-specific CD8+ T cells through the regulation of the migration of CD8+ T cells and DCs in TME. Thus, AXL may be a powerful molecular target to improve anti-cancer effects through single or combined therapy with immune checkpoint inhibitors (ICI).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
- Department of Biomedical Sciences, Asan Medical Center, AMIST, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
- Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
- Department of Cell and Genetic Engineering, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea.
- Department of Biochemistry and Molecular Biology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, 05505, South Korea. Electronic address: jkrho@amc.seoul.kr.
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Health and Welfare
Zitieren
APA
Im, K., Choi, Y. J., Kim, D. H., Kim, D. S., Ban, K., Ji, W., Baek, I. J., Choi, C. M., Lee, J. C., & Rho, J. K. (2023). AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming. Biochemical and Biophysical Research Communications, 680, 7-14. https://doi.org/10.1016/j.bbrc.2023.09.021
Vancouver
Im K, Choi YJ, Kim DH, Kim DS, Ban K, Ji W, et al. AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming. Biochemical and Biophysical Research Communications. 2023;680:7-14. doi:10.1016/j.bbrc.2023.09.021
BibTeX
@article{Im2023,
author = {Im, Kyungtaek and Choi, Yun Jung and Kim, Dong Ha and Kim, Da-Som and Ban, Kyosun and Ji, Wonjun and Baek, In-Jeoung and Choi, Chang-Min and Lee, Jae Cheol and Rho, Jin Kyung},
title = {AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
volume = {680},
pages = {7--14},
doi = {10.1016/j.bbrc.2023.09.021}
}
EUVIMED